B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307
B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307
美國銀行證券維持對阿里拉姆製藥的買入評級，將目標股價上調至307美元
B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $295 to $307.
B of A Securities分析師Tazeen Ahmad維持Alnylam Pharmaceuticals（NASDAQ:ALNY）的買入評級並將目標股價從$295上調至$307。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。